NeuroOne Medical Technologies AI Stock Analysis
Want to see NMTC full AI Analyst Report?
NeuroOne Medical Technologies (NMTC) AI Stock Analysis
NeuroOne Medical Technologies
(NASDAQ:NMTC)
The score is held down primarily by weak financial quality—very large operating losses and meaningful cash burn—despite strong revenue growth and low leverage. Technicals add additional pressure given the clear downtrend and negative momentum, even though the stock appears oversold. Positive corporate events (revenue strength, record purchase order, and product development progress) provide some offset, while valuation is difficult to assess due to a negative P/E and no dividend yield.
NeuroOne Medical Technologies (NMTC) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $6.43M
- Dividend Yield
- ―
- Average Volume (3M)
- 336.58K
- Price to Earnings (P/E)
- -0.8
- Beta (1Y)
- 1.47
- Revenue Growth
- -1.67%
- EPS Growth
- 7.34%
- Country
- US
- Employees
- 18
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
NeuroOne Medical Technologies Business Overview & Revenue Model
Company Description
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neur...
How the Company Makes Money
NeuroOne makes money primarily by selling its neurostimulation and neurodiagnostic device products (notably thin-film electrode arrays and associated components) to healthcare providers and/or through distribution partners. Revenue is generated on a...
NeuroOne Medical Technologies Earnings Call Summary
The call delivered strong operational and clinical progress — including double-digit revenue growth (+16% YoY), 43% growth in orders, improved gross margins (+6.0 percentage points), ISO 13485 certification, and meaningful advances across product lines (OneRF, Trigeminal, StereoCED, BVNA). However, these positives are balanced by material near-term challenges: manufacturing lead times and backlog that constrain revenue recognition, rising operating expenses and widening net loss, and a significant decline in cash and working capital that creates liquidity pressure. Management has mitigation plans (second manufacturing site, ATM raises, supply acceleration) and clear clinical/regulatory milestones, but the financial and execution risks temper the upside from operational wins.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Guidance for fiscal 2026 reiterated expected aggregate product orders of approximately $11.2 million and recognized revenue of $9.2–$10.5 million (timing-dependent); Q3 product revenue was $2.0M (up 16% YoY from $1.7M) with $2.7M of orders in the quarter (up 43% YoY) and a $1.7M backlog as of June 30, 2026 that management expects to address by the end of calendar Q4 2026 through supplier acceleration and qualification of a second, larger manufacturing site expected in early 2027. Gross margin expanded to 59.9% (product gross profit $1.2M vs 53.9% a year ago), total operating expenses were $3.6M (R&D $1.4M; SG&A $2.2M), net loss was $2.0M ($0.23 basic / $0.28 diluted) versus $1.5M ($0.19 / $0.22) prior-year, cash and cash equivalents were $2.0M (vs $6.6M on 9/30/25) with $1.1M AR expected to convert in Q4, working capital $3.7M (vs $7.9M), no debt, and $1.4M raised via ATM in 2026 ($0.4M in Q3; $1.0M on July 13 via 400,346 shares); strategic milestones/timing include ISO 13485 certification enabling international expansion, StereoCED aimed for investigational human studies by end-September 2026, and a BVNA 510(k) submission targeted in H2 2027, while a lead investor increased ownership from 7.4% to 12.5%.
NeuroOne Medical Technologies Financial Statement Overview
Summary
Revenue is ramping quickly into TTM (~$10.0M) with improving gross margin versus earlier years, but operating performance remains severely negative (EBIT margin ~-80%, net margin ~-72%). Cash flow is a major weakness with substantial and worsening burn (TTM operating cash flow ~-$7.1M; FCF ~-$7.2M). The balance sheet helps somewhat due to minimal debt (~$0.07M; debt-to-equity ~0.02), but equity has fallen meaningfully (FY2025 ~$7.1M to TTM ~$3.8M), reflecting ongoing losses.
Income Statement
27NegativeBalance Sheet
58NeutralCash Flow
24Negative| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.00M | 12.10M | 3.45M | 1.95M | 171.17K | 178.15K |
| Gross Profit | 5.57M | 8.14M | 1.08M | 456.52K | -70.79K | -97.75K |
| EBITDA | -6.91M | -3.01M | -11.84M | -11.66M | -9.88M | -9.86M |
| Net Income | -7.15M | -3.61M | -12.32M | -11.86M | -10.00M | -9.95M |
Balance Sheet | ||||||
| Total Assets | 6.19M | 10.79M | 5.37M | 8.10M | 12.82M | 7.94M |
| Cash, Cash Equivalents and Short-Term Investments | 2.05M | 6.57M | 1.46M | 5.32M | 11.14M | 6.90M |
| Total Debt | 73.32K | 266.81K | 260.16K | 184.40K | 202.90K | 315.67K |
| Total Liabilities | 2.42M | 3.71M | 4.55M | 1.85M | 3.22M | 1.38M |
| Stockholders Equity | 3.77M | 7.07M | 822.01K | 6.25M | 9.60M | 6.55M |
Cash Flow | ||||||
| Free Cash Flow | -7.16M | -2.92M | -11.13M | -13.27M | -7.79M | -8.67M |
| Operating Cash Flow | -7.05M | -2.84M | -11.01M | -12.89M | -7.52M | -8.60M |
| Investing Cash Flow | -109.54K | -81.74K | -120.20K | 2.65M | -3.24M | -67.08K |
| Financing Cash Flow | 1.17M | 8.33M | 7.27M | 7.40M | 12.02M | 11.53M |
NeuroOne Medical Technologies Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NMTC, the sentiment is Negative. The current price of 0.71 is below the 20-day moving average (MA) of 0.86, below the 50-day MA of 1.08, and below the 200-day MA of 2.93, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 30.72 is Neutral, neither overbought nor oversold. The STOCH value of -0.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NMTC.
NeuroOne Medical Technologies Risk Analysis
NeuroOne Medical Technologies disclosed 51 risk factors in its most recent earnings report. NeuroOne Medical Technologies reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksNeuroOne Medical Technologies Peers Comparison
Overall Rating
NMTC47Neutral
SRTS45Neutral
ECOR42Neutral
RBOT40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | $6.43M | -0.77 | -126.45% | ― | -1.67% | 7.34% | |
| 45Neutral | $37.20M | -2.31 | -38.65% | ― | -53.33% | -429.93% | |
| 42Neutral | $44.19M | -3.31 | 498.83% | ― | 27.26% | 20.47% | |
| 40Underperform | $2,282 | 0.00 | -333.19% | ― | ― | 36.00% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NMTC | Neuroone Medical Technologies Corporation | 0.71 | -2.90 | -80.42% | |
| SRTS | Sensus Healthcare, Inc. | 2.26 | -1.67 | -42.49% | |
| ECOR | Electrocore | 4.79 | 0.20 | 4.36% | |
| MODD | Modular Medical Inc. | 1.80 | -11.61 | -86.58% | |
| RBOT | Vicarious Surgical Inc. | 0.02 | -2.56 | -99.22% |
NeuroOne Medical Technologies Corporate Events
NeuroOne Reports Strong Fiscal 2026 Revenue Growth
PositiveOn October 5, 2026, NeuroOne reported preliminary, unaudited fiscal 2026 product revenue of approximately $10.5 million, a 15.6% increase year over year and at the top of its guidance range. The company also disclosed preliminary fourth-quarter produ...
NeuroOne Advances StereoCED Toward Human Clinical Studies
PositiveOn August 27, 2026, NeuroOne reported the successful completion of three large-animal procedures at the University of Minnesota using its next-generation StereoCED platform for robotic-assisted intracerebral drug delivery and electrophysiological mon...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 05, 2026
